Our core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose disease from a simple blood test.


This technology is applicable to a wide range of diseases, including prostate, brain, pancreatic, and blood cancers as well as cardiovascular and neuro-degenerative diseases.


ClarityDX Prostate, our lead product currently in clinical trials, is designed to be a highly accurate test to predict clinically significant prostate cancer.This technology is positioned to emerge as the leading diagnostic tool, bringing clarity to healthcare decisions for prostate cancer.

Please note: this product is in development and so currently has not received regulatory approval or clearance in any markets.


Nanostics is a Canadian company with offices in Edmonton, Alberta. The company is privately held by the founders and a small group of investors.

Please contact us about opportunities to invest in Nanostics.

Nanostics corporate brochure October 1, 2018

Our success would not be possible without the support of our many Canadian and international collaborators, funders and partners.